KCT0005113
Recruiting
未知
A prospective, phase II study evaluating the efficacy of intraoperative radiotherapy after neoadjuvant chemotherapy in patients with resectable pancreatic cancer
Yonsei University Health System, Gangnam Severance Hospital0 sites80 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Yonsei University Health System, Gangnam Severance Hospital
- Enrollment
- 80
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •? Histologic diagnosis or clinically suspected of adenocarcinoma of the pancreas based on imaging tests or tumor markers
- •? Older than 20 years
- •? The performance status of patients based ECOG score less than 3
- •? Patients with pancreatic cancer who were either surgically resectable or borderline resectable or can be resected after neoadjuvant chemotherapy because of advanced pancreatic cancer
- •? Patients who voluntarily decided to participate in this clinical study and signed the written informed consent
Exclusion Criteria
- •? Previous history of irradiation in abdomen
- •? The treatment site could not be included in the appropriate radiation field, as judged by the radiation oncologist or the surgeon
- •? In case of distant metastasis
- •? A systemic condition that, under the judgment of the attending physician, would be difficult for surgery or radiation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Clinical trial to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multiple myeloma who did not responded after previous high-dose therapyMultiple myelomaTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2014-000130-37-ITFONDAZIONE NEOPLASIE SANGUE ONLUS (FO.NE.SA. Onlus)73
Recruiting
Phase 2
A phase II study to evaluate the effectiveness of S-1 + Cetuximab for patients with advanced/recurrent colon cancer who cannot undergo intensive therapyadvanced/recurrent colon cancer patients with RAS wild-type tumors who cannot undergo intensive therapyJPRN-UMIN000018484HO HOKKAIDO CANCER CENTER Division of Gastroenterology57
Active, not recruiting
Not Applicable
A Pilot Phase II Study for the evaluation of efficacy and tolerability of Gammaidroxybutyrate (ALCOVER) administered by oral route as add on treatmant in patients affected by DYT 11 Myoclonic Dystonia. - NDEUCTR2006-001039-23-ITISTITUTO NEUROLOGICO CARLO BESTA
Active, not recruiting
Phase 1
A phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failureRecurrent unresectable or metastatic cervix carcinomaMedDRA version: 21.1Level: PTClassification code 10008344Term: Cervix carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-002184-97-FRCentre François Baclesse57
Active, not recruiting
Not Applicable
Prospective phase II trial evaluating efficacy of Trastuzumab therapy in HER2 FISH positive and/or HER2 mutation positive, pretreated, Non-Small Cell Lung Cancer patients (MO20509) - NDEUCTR2007-003709-29-ITISTITUTO CLINICO HUMANITAS